Comments
Suven Life Sciences on Wednesday announced the grant of a product patent from Aripo (AP4415) and one product patent from South Korea (10-18087922) corresponding to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2033 and 2034, respectively. These are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, narcolepsy, Parkinson’s and schizophrenia, respectively. The stock of Suven Life slipped 4.2 per cent at ₹215 on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.